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[Plain language summary](https://doi.org/10.1111/bjd.17665) available online

Systemic immunomodulatory therapies form a key part of the treatment of moderate‐to‐severe atopic eczema (AE, syn. 'atopic dermatitis') where topical or phototherapy alone is not sufficient to induce disease remission and maintain long‐term symptom control.[1](#bjd16714-bib-0001){ref-type="ref"}

With the exception of ciclosporin and dupilumab these therapies are prescribed off‐label;[2](#bjd16714-bib-0002){ref-type="ref"}, [3](#bjd16714-bib-0003){ref-type="ref"}, [4](#bjd16714-bib-0004){ref-type="ref"} nevertheless, immunomodulatory therapies are frequently prescribed in both children and adults.[5](#bjd16714-bib-0005){ref-type="ref"}, [6](#bjd16714-bib-0006){ref-type="ref"}, [7](#bjd16714-bib-0007){ref-type="ref"} However, long‐term use may be limited due to adverse effects. There is also only a small body of randomized controlled trials (RCTs) to guide clinical management.[8](#bjd16714-bib-0008){ref-type="ref"}, [9](#bjd16714-bib-0009){ref-type="ref"}, [10](#bjd16714-bib-0010){ref-type="ref"}, [11](#bjd16714-bib-0011){ref-type="ref"}

There is a need to gather long‐term, comparative and real life data on effectiveness, safety and cost‐effectiveness of these therapies in large‐scale multicentre registries beyond the confines of short‐term RCTs[12](#bjd16714-bib-0012){ref-type="ref"} at the time when novel biological and small‐molecule therapies are entering clinical practice.

The TREatment of ATopic eczema (TREAT) Registry Taskforce aims to find consensus on core domains and domain items for AE research registries and to harmonize data collection on patients receiving photo‐ and systemic immunomodulatory therapies. The ultimate goal is to reduce heterogeneity between national AE patient registries, allow direct comparability of individual country data and facilitate potential data pooling between countries.

Heterogeneity of outcomes (i.e. domains) used in disease (e.g. psoriasis) registries has been demonstrated to hinder comparing results and pooling of data between centres and countries.[13](#bjd16714-bib-0013){ref-type="ref"} Therefore the development of an *a priori* internationally agreed core set of variables[14](#bjd16714-bib-0014){ref-type="ref"} (i.e. an agreed‐on minimum set of variables that should be measured and reported by every registry) is essential, as indicated by the guideline of the European Commission‐funded PAtient REgistries iNiTiative joint action (PARENT JA).[15](#bjd16714-bib-0015){ref-type="ref"}

The objective of this Delphi study was to reach international consensus between different stakeholders on a core set of domains and items ('what to measure') for existing and future AE patient registries with a research focus, that collect data of children and adults on photo‐ and systemic immunomodulatory therapies.

Methods {#bjd16714-sec-0007}
=======

This study was registered in the Core Outcome Measures for Effectiveness Trials (COMET) database ([www.comet-initiative.org/studies/details/825?result=true](http://www.comet-initiative.org/studies/details/825?result=true)) and reported following the recommended checklist of Sinha *et al*.[16](#bjd16714-bib-0016){ref-type="ref"} and Core Outcome Set‐STAndards for Reporting (COS‐STAR) statement.[17](#bjd16714-bib-0017){ref-type="ref"} The protocol has been published previously.[18](#bjd16714-bib-0018){ref-type="ref"}

In brief, an online Delphi exercise (i.e. 'eDelphi') and a subsequent consensus meeting were conducted to investigate domains and items of importance. The eDelphi included three sequential rounds answered anonymously by key stakeholder groups to avoid participants being influenced by opinions of other group members and to minimize response bias. After each round, a summary of the responses was fed back to the group. Individual participants could then decide to keep their original answers or to change their opinion in the next round, considering responses from the other participants. The total number of registered participants for each round was recorded as the number of participants who had completed the rating. Reasons for changes to scores were documented by asking participants at the end of rounds 2 and 3 to give a general view of why they changed their scores.

Participants and recruitment {#bjd16714-sec-0008}
----------------------------

Representatives from six key stakeholder groups[19](#bjd16714-bib-0019){ref-type="ref"} were invited:

Healthcare professionals: doctors who care for patients with moderate‐to‐severe AE.Healthcare professionals: nurses who care for patients with moderate‐to‐severe AE.Nonclinical researchers with active research interest in AE, e.g. methodologists, epidemiologists, health economists.Patients: adults and carers of children or adults with AE.Industry representatives involved in the development of systemic immunomodulatory drugs for AE.Regulatory body representatives from the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and national regulatory bodies, such as the U.K. National Institute for Health and Care Excellence (NICE).

Groups 1--3 had representation from members of relevant international societies registered with the International League of Dermatological Societies (ILDS) and other relevant special interest groups \[e.g. International Eczema Council, European Taskforce for Atopic Dermatitis, European network of psoriasis patients registries (PSONET) as well as the German AE systemic therapy and hand dermatitis registries\] from different parts of the world. These societies were asked to send out an e‐mail with the link to our eDelphi. Patient representatives were recruited from national eczema support groups (see Table [2](#bjd16714-tbl-0002){ref-type="table"} of the protocol published by Gerbens *et al*.[18](#bjd16714-bib-0018){ref-type="ref"}), again by e‐mail invitation. Groups 5 and 6 were identified through personal contacts from Europe and the U.S.A.

Members of the TREAT research group (C.A., S.B., R.B., A.B., M.D., C.F., L.G., A.I., P.M‐H., A.R., J.S., P.S., C.V., D.W. and S.W.; see treat‐registry‐taskforce.org/centres) participated in the eDelphi as well as in the consensus meeting.

eDelphi questionnaire {#bjd16714-sec-0009}
---------------------

Based on a systematic search of the literature, decisions already made on core outcomes by the Harmonising Outcome Measures for Eczema (HOME) initiative and round table discussion within the TREAT research group, 119 domains (i.e. high‐level data, e.g. physical examination) and items (i.e. more granular data, e.g. blood pressure) were initially identified; a proposed list of 89 domains items mapped to domains (Table S1; see Supporting Information) together with an obvious list of 30 domains and items (Table S2; see [Supporting Information](#bjd16714-sup-0001){ref-type="supplementary-material"}). The 'obvious' list included items that were considered obvious, e.g. age, and were therefore not included in the eDelphi but listed separately.

Patients additionally reviewed the questionnaire concerning content and language.

eDelphi survey {#bjd16714-sec-0010}
--------------

A pilot‐tested online e‐management survey system, DelphiManager, maintained by the COMET Initiative, was used.[20](#bjd16714-bib-0020){ref-type="ref"} At the beginning of each round, the details of the study with key objectives were presented. Subsequently, participants were asked to rate each of the domain items using the Grading of Recommendations Assessment, Development and Evaluations (GRADE) scale, a 9‐point scale with 1 to 3 labelled 'not important'; 4 to 6 'important but not critical'; and 7 to 9 'critical' (see Fig. S1 for examples of how the results were presented to participants; Supporting Information).[21](#bjd16714-bib-0021){ref-type="ref"} Participants had the option of selecting 'unable to score' if they felt unable to rate, and of providing feedback on a specific item or in general at the end of the survey. Hovering over the text provided an explanation for key terms.

The system asked participants to complete each round and reminder e‐mails were sent to increase the response rate. To reduce the risk of attrition bias, the importance of completing all rounds was highlighted at the outset of each round.

Definition of consensus and core set {#bjd16714-sec-0011}
------------------------------------

The definition of consensus for the eDelphi was based on that proposed by Harman *et al*.,[22](#bjd16714-bib-0022){ref-type="ref"} but amended to take into consideration the multiple stakeholder groups. This definition ensures that the vast majority considers an item critically important in the absence of a sizeable minority thinking the opposite. Consensus that a domain item should be included in the core set ('consensus in') was defined as 70% or more of participants in each stakeholder group scoring its importance as 7 to 9 and less than 15% scoring it as 1 to 3. For 'consensus out' it was the other way around. If there was no consensus 'in' or 'out', it was referred to as 'no consensus'. Any item where all groups confirmed 'consensus in' was taken to be in the core set.

After round 3 the following definition of 'consensus out' was used for feasibility reasons (deviation from the protocol): domain items that had not met the threshold for 'consensus in' and were rated 'critical' by less than 50% in all groups (excluding regulatory bodies, as there were only two of them in round 3 and none at the meeting) were categorized as 'no consensus, no voting required' and assumed to be excluded from the core set. Further, those that had not met the threshold for 'consensus in' but were rated 'critical' by at least 50% in at least one group were categorized as 'no consensus, voting required'. Overall this led to the classification of each domain item as 'consensus in', 'no consensus, no voting required' or 'no consensus, voting required' after round 3.

The definition of consensus for the consensus meeting was that used by the Outcome Measures in Rheumatology collaboration (OMERACT) group and HOME initiative.[23](#bjd16714-bib-0023){ref-type="ref"}, [24](#bjd16714-bib-0024){ref-type="ref"}, [25](#bjd16714-bib-0025){ref-type="ref"} 'Consensus in' was defined as: less than 30% of the whole group of participants disagree.

eDelphi round 1 {#bjd16714-sec-0012}
---------------

Information collected in round 1 included: (i) participants' characteristics (Table [1](#bjd16714-tbl-0001){ref-type="table"}); (ii) the obvious list to be reviewed and potentially commented on; (iii) the proposed list to be scored; and (iv) an option to add additional domains or items.

###### 

Characteristics of participants in the eDelphi and consensus meeting

                                                                              Participants registered (*n* = 479) (%)   Participants completing R1 and included in next rounds (*n* = 410) (%)   Participants consensus meeting (*n* = 42) (%)
  --------------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------------ -----------------------------------------------
  Stakeholder group[a](#bjd16714-note-0006){ref-type="fn"}                                                                                                                                       
  Doctors                                                                     335 (69·9)                                302 (73·7)                                                               19 (45·2)
  Nurses                                                                      30 (6·3)                                  21 (5·1)                                                                 6 (14·3)
  Patients                                                                    76 (15·9)                                 52 (12·7)                                                                6 (14·3)
  Researchers                                                                 16 (3·3)                                  16 (3·9)                                                                 3 (7·1)
  Industry                                                                    16 (3·3)                                  14 (3·4)                                                                 8 (19·1)
  Regulatory bodies                                                           6 (1·3)                                   5 (1·2)                                                                  --
  Age (years)                                                                                                                                                                                    
  18--30                                                                      38 (7·8)                                  24 (5·9)                                                                 --
  31--40                                                                      124 (25·9)                                102 (24·9)                                                               --
  41--50                                                                      145 (30·3)                                125 (30·5)                                                               --
  51--60                                                                      125 (26·1)                                114 (27·8)                                                               --
  \> 60                                                                       47 (9·8)                                  45 (11)                                                                  --
  Sex                                                                                                                                                                                            
  Female                                                                      300 (62·6)                                249 (60·7)                                                               25 (60)
  Male                                                                        177 (37)                                  159 (38·8)                                                               17 (40)
  Other                                                                       2 (0·4)                                   2 (0·5)                                                                  --
  Countries (according to continent)                                                                                                                                                             
  Africa                                                                      3 (0·6)                                   1 (0·2)                                                                  --
  Asia                                                                        54 (11·3)                                 49 (12)                                                                  --
  Europe                                                                      348 (72·7)                                292 (71·2)                                                               39 (92·8)
  North America                                                               35 (7·3)                                  33 (8)                                                                   1 (2·4)
  Oceania                                                                     34 (7·1)                                  30 (7·3)                                                                 --
  South America                                                               5 (1)                                     5 (1·2)                                                                  2 (4·8)
  Total countries participating                                               39                                        36                                                                       13
  Characteristics of healthcare professionals (i.e. doctors and nurses)                                                                                                                          
  *Current position*                                                                                                                                                                             
  University teaching hospital                                                288 (78·9)                                260 (80·4)                                                               --
  Other hospital                                                              48 (13·2)                                 38 (11·8)                                                                --
  Community setting                                                           19 (5·2)                                  18 (5·6)                                                                 --
  Other, e.g. private practice                                                10 (2·7)                                  7 (2·2)                                                                  --
  *Age group of patients with AEs that participants predominantly care for*                                                                                                                      
  Paediatric                                                                  208 (57)                                  183 (56·7)                                                               --
  Adult                                                                       151 (41·4)                                137 (42·4)                                                               --
  N/A (retired, university setting without patients)                          6 (1·6)                                   3 (0·9)                                                                  --
  *Experience in care of patients with AEs*                                                                                                                                                      
  \< 10 years                                                                 113 (31)                                  98 (30·3)                                                                --
  \> 10 years                                                                 248 (67·9)                                224 (69·3)                                                               --
  Did not answer                                                              4 (1·1)                                   1 (0·3)                                                                  --
  *Membership of international dermatology society or AE interest group*                                                                                                                         
  Yes                                                                         246 (67·4)                                224 (69·3)                                                               --
  No                                                                          116 (31·8)                                98 (30·3)                                                                --
  Did not answer                                                              3 (0·8)                                   1 (0·3)                                                                  --

AE, atopic eczema; N/A, not applicable; R, round

^a^Participants themselves decided their stakeholder group from a drop‐down menu.
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eDelphi round 2 {#bjd16714-sec-0013}
---------------

All domain items were carried through to the second round, together with additional domain items listed by participants in round 1 after deduplication by the TREAT group. Participants were asked to rate them. They were presented with the number of participants who scored each category and the distribution of scores (%) for each domain item for their particular stakeholder group with a reminder of their own round 1 score.

Those who had not participated in or completed the first round were not invited to round 2.

eDelphi round 3 {#bjd16714-sec-0014}
---------------

All domain items were carried forward into round 3. All participants received identical feedback, containing the distribution of scores (%) for each domain item for all stakeholder groups, along with a reminder of their own round 2 score.

All participants included in round 2 were invited for round 3.

Consensus meeting {#bjd16714-sec-0015}
-----------------

A face‐to‐face meeting was held in Amsterdam on 25 October 2016. Representation of all eDelphi stakeholder groups was attempted, but healthcare professionals and patients were of particular importance. The travel expenses of participating patients was covered by the funds held by C.F. and P.S. A patient pre‐meeting, attended by six patients, was held to empower patients and to encourage them to express their views during the main consensus meeting. The main meeting was moderated by one nonvoting independent participant (P.W.), with extensive experience in the conduct of international Delphi exercises, who ensured that the voices of all representative groups were heard, and the discussions and decision‐making process were not dominated by individual participants. The nominal group technique was used.[26](#bjd16714-bib-0026){ref-type="ref"}, [27](#bjd16714-bib-0027){ref-type="ref"}

The facilitator presented the response rates of each eDelphi round and the results of round 3 according to the three above‐mentioned categories of classification. The domain items in the categories 'consensus in' and 'no consensus, no voting' were not voted on, unless reasons were very strong and transparent. The same applied for opening discussion around new domains or items. For the last category 'no consensus, voting required', discussion and voting took place, anonymized by using TurningPoint^©^ electronic handsets and software version 5·0 for Windows (Turning Technologies, Youngstown, OH, U.S.A.) to analyse results in real time.

Participants completed a conflict of interest form.

Data management {#bjd16714-sec-0016}
---------------

Confidentiality of survey data was ensured using unique numerical identifiers. Data were password protected and accessible only to the TREAT research group, who under no circumstances breached confidentiality. SPSS version 22·0 for Windows (SPSS, Inc., Chicago, IL, U.S.A.) and R version 3·3·3 (The R Foundation) were used to perform statistical analyses.

Ethical requirements {#bjd16714-sec-0017}
--------------------

Consent to participate was assumed if individuals registered and completed rounds. Consent to list participants in the acknowledgments was assumed if participants completed all Delphi rounds as this was stated beforehand in the invitation letter for the consensus exercise.

The Medical Ethics Review Committee of the Academic Medical Centre in Amsterdam (reference number W15_249 \# 15·0294) confirmed that the Medical Research Involving Human Subjects Act (WMO) did not apply to this study.

Results {#bjd16714-sec-0018}
=======

Participants' characteristics {#bjd16714-sec-0019}
-----------------------------

Of the 479 registered participants, 410 completed round 1 and were included in the next round. Six stakeholder groups were involved; 302 (74%) doctors, 21 (5%) nurses, 52 (13%) patients, 16 (4%) researchers, 14 (3%) industry representatives and five (1%) regulatory body representatives. Participants originated from 36 countries, mainly from Europe. (See Table [1](#bjd16714-tbl-0001){ref-type="table"}).

Response rates and change in participant score {#bjd16714-sec-0020}
----------------------------------------------

Rounds 1--3 reached a response rate of 86% (410/479), 79% (325/410) and 74% (303/410), respectively. Dropout rates per stakeholder group are presented in Table [2](#bjd16714-tbl-0002){ref-type="table"}.

###### 

Dropout rates of the eDelphi

  Initial participation         Dropouts (%); R1 and R2   Dropouts (%); R1--R3
  ----------------------------- ------------------------- ----------------------
  Doctors (*n* = 302)           55 (18)                   69 (23)
  Nurses (*n* = 21)             6 (29)                    7 (33)
  Patients (*n* = 52)           12 (23)                   18 (35)
  Researchers (*n* = 16)        2 (13)                    2 (13)
  Industry (*n* = 14)           7 (50)                    8 (57)
  Regulatory bodies (*n* = 5)   3 (60)                    3 (60)
  Overall (*n* = 410)           85 (21)                   107 (26)

R, round

John Wiley & Sons, Ltd

Participants changed scores between the different subsequent rounds. Common reasons mentioned were: that responses of others convinced them; they\'d had second thoughts; items were not important enough for the core set; or they misread the question the first time.

eDelphi rounds 1--3 {#bjd16714-sec-0021}
-------------------

A flowchart of identification and selection of core domain items is shown in Figure [1](#bjd16714-fig-0001){ref-type="fig"}.

![Flowchart of identification and selection of core domains and domain items. 'Obvious': domains and items that were considered obvious to be included in AE registries by the TREAT research group, e.g. age and sex, and were therefore not included in the eDelphi. 'Proposed': domain items proposed to register by the TREAT research group and included in the eDelphi. 'Additional': domain items added by participants in round 1 of the eDelphi. 'Consensus in': defined as 70% or more of participants in each stakeholder group scoring the importance of a domain item as 7--9 and less than 15% scoring it as 1--3; included in the core set. 'Consensus out': the other way around. 'No consensus, voting required': domain items that did not meet the threshold for 'consensus in' but were rated 'critical' by at least 50% in at least one group. 'No consensus, no voting required': domain items that did not meet the threshold for 'consensus in' and were rated critical by less than 50% in all groups; excluded from the core set. AE, atopic eczema; TREAT,TREatment of ATopic eczema.](BJD-180-790-g001){#bjd16714-fig-0001}

A total of 119 domain items were included in round 1: the proposed list (*n* = 89) (Table [S1](#bjd16714-sup-0001){ref-type="supplementary-material"}; see Supporting Information) and obvious list (*n* = 30) (Table [S2](#bjd16714-sup-0001){ref-type="supplementary-material"}; see Supporting Information). The obvious list was not included for voting, but participants could comment on domains and items to be changed or excluded from the list and included for voting in round 2. However, no changes were made to the list. Participants suggested 105 additional domain items in round 1. After deleting duplicates, 47 were added to round 2 (Table [S3](#bjd16714-sup-0001){ref-type="supplementary-material"}; see Supporting Information).

In round 2 participants voted on 136 domain items (proposed and additional list). After voting, 19 domain items reached consensus to be included in the core set, in addition to the a priori defined obvious list (Table [S3](#bjd16714-sup-0001){ref-type="supplementary-material"}).

All items were then taken into round 3, including those that reached 'consensus in'. There were 29 domain items that reached 'consensus in'; 0 'consensus out'; and 37 'no consensus, no voting required', leaving 70 domain items without consensus and required voting (Table [S3](#bjd16714-sup-0001){ref-type="supplementary-material"}). These were subsequently considered in the consensus meeting.

Consensus meeting {#bjd16714-sec-0022}
-----------------

Minutes of the meeting are available online at treat‐registry‐taskforce.org. Forty‐two participants (Table [1](#bjd16714-tbl-0001){ref-type="table"}), representing all stakeholder groups except regulatory bodies, ratified the 30 obvious and 29 domain items for which 'consensus in' was reached. Six of the 29 items were merged into three by discussion and voting, i.e. 'follow‐up reporting of disease control by physician' with 'follow‐up reporting of disease control by patient' into 'follow‐up reporting of disease control' (93% consensus), 'dermatology‐specific quality of life (QoL) score' with 'AE‐specific QoL score' into 'skin‐specific QoL score' for both baseline and follow‐up (77% consensus). The two 'disease control' items were combined as this core domain is still under research by the HOME initiative.[28](#bjd16714-bib-0028){ref-type="ref"} Merging of 'QoL scores' was done as the opinion was that too many items on QoL in the core set would overburden patients.

Discussion and voting was performed for the remaining 70 domain items where 'no consensus, voting required' had been reached. Twelve (5 from the proposed and 7 from the additional list) were added, making a total of 38 domain items that reached consensus to be included in the core set together with the 30 obvious items (Table [3](#bjd16714-tbl-0003){ref-type="table"}; Tables [S3](#bjd16714-sup-0001){ref-type="supplementary-material"} and [S4](#bjd16714-sup-0001){ref-type="supplementary-material"}; see Supporting Information). The items concerning frequency of safety investigations and follow‐up frequency for registry data entry were not voted on, as they were considered to be part of the 'when to measure' instead of the 'what to measure'.

###### 

Core set of domains and domain items

  Domains                                             Obvious/proposed/additional[\[Link\]](#bjd16714-note-0009){ref-type="fn"}   Domain items
  --------------------------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------
  Demographics                                        Obvious                                                                     Date of birth and date of enrolment into registry
                                                                                                                                  Sex
                                                                                                                                  Ethnicity
                                                                                                                                  Educational status
                                                                                                                                  Current occupation or education
  AE diagnosis                                        Obvious                                                                     How diagnosis AE is established
                                                                                                                                  Use of validated diagnostic criteria
                                                                                                                                  Date of onset AE
  Past AE treatments                                  Obvious                                                                     Phototherapy
                                                                                                                                  Systemic therapy
                                                      Proposed                                                                    Topical treatments for AE
                                                                                                                                  Day hospital care treatments for AE (outpatient)
                                                                                                                                  Hospitalization for AE
  Current AE treatments                               Obvious                                                                     Phototherapy
                                                                                                                                  Systemic therapy
                                                      Proposed                                                                    Topical treatments
                                                      Additional                                                                  Amount of topical creams/ointments used per week
  Family history of AE or allergic diseases           Obvious                                                                     Family history of AE or allergic diseases
  Allergic comorbidities                              Obvious                                                                     Asthma
                                                                                                                                  Allergic rhinoconjunctivitis
                                                                                                                                  Atopic eye disease
                                                                                                                                  Eosinophilic oesophagitis
                                                                                                                                  Food allergies
                                                                                                                                  Contact allergies
  Other comorbidities                                 Obvious                                                                     Malignancies
                                                                                                                                  Serious infections
  Current concomitant medication                      Proposed                                                                    Antihistamines, oral or topical
                                                                                                                                  Antibiotics, oral or topical[\[Link\]](#bjd16714-note-0010){ref-type="fn"}
                                                      Additional                                                                  Immunosuppressives for other inflammatory diseases
  Baseline general AE questions                       Additional                                                                  Exposures that trigger disease flares
                                                                                                                                  Episodes of skin infection (i.e. folliculitis, HSV, molluscum contagiosum)
                                                                                                                                  Days lost from usual activities
  Baseline physical examination                       Proposed                                                                    Fitzpatrick skin type
                                                                                                                                  Skin examination
  Baseline physician‐ and patient‐reported domains    Proposed                                                                    Physician‐assessed clinical signs
                                                      Investigator/physician global assessment                                    
                                                                                                                                  Patient‐reported symptoms
                                                                                                                                  Patient global assessment
                                                                                                                                  Generic quality of life score
                                                                                                                                  Skin‐specific quality of life score
                                                                                                                                  Patient‐reported satisfaction with AE care received
                                                      Additional                                                                  Impact of AE on the family
  Baseline investigations                             Obvious                                                                     Medical history (tuberculosis, HIV, hepatitis B or C)
                                                                                                                                  Full blood count
                                                                                                                                  Liver function
                                                                                                                                  Kidney profile
                                                      Proposed                                                                    Evaluating TPMT level prior to azathioprine use
  Baseline management                                 Proposed                                                                    Main reasons for choosing specific treatment (systemic or phototherapy)
                                                                                                                                  Relative contraindication(s) for selected treatment
  Follow‐up general AE questions                      Additional                                                                  Days lost from usual activities[\[Link\]](#bjd16714-note-0010){ref-type="fn"}
                                                                                                                                  Change in diagnosis after enrolment (e.g. from AE to CTCL)
                                                                                                                                  Date of death and relation to AE
  Follow‐up physical examination                      Proposed                                                                    Skin examination
  Follow‐up physician‐ and patient‐reported domains   Proposed                                                                    Physician‐assessed clinical signs
                                                      Investigator/physician global assessment                                    
                                                                                                                                  Patient‐reported symptoms
                                                                                                                                  Patient global assessment
                                                                                                                                  Generic quality of life score
                                                                                                                                  Skin‐specific quality of life score
                                                                                                                                  Reporting of disease control
                                                                                                                                  Adherence to treatment between appointments
                                                                                                                                  Patient‐reported satisfaction with AE care received
                                                      Additional                                                                  Impact of AE on the family
  Follow‐up investigations                            Obvious                                                                     Safety bloods[\[Link\]](#bjd16714-note-0010){ref-type="fn"}
  Follow‐up adverse events                            Obvious                                                                     Serious adverse events
                                                                                                                                  Adverse events that cause stop or switch of therapy or change in dosage
                                                                                                                                  *For (serious) adverse events*: probability of relationship with treatment
  Follow‐up management                                Obvious                                                                     Reason for switching therapy
                                                                                                                                  Reason for discontinuation of therapy

AE, atopic eczema; CTCL, cutaneous T‐cell lymphoma; HIV, human immunodeficiency virus; HSV, herpes simplex virus; TPMT, thiopurine methyltransferase.

Obvious: domains and items that were considered obvious to be included in AE registries by the TREAT research group, e.g. age and sex, and were therefore not included in the eDelphi. Proposed: domains and items proposed to register by the TREAT research group and included in the eDelphi. Additional: domains and items added by participants in round 1 of the eDelphi.

These items were merged (i.e. 'antibiotics oral' and 'antibiotics topical' to 'antibiotics, oral or topical') or added \[i.e. 'days lost from usual activities' (follow‐up) and 'safety bloods' (follow‐up)\] after the eDelphi and consensus meeting.

John Wiley & Sons, Ltd

After a final discussion within the TREAT research group the items 'antibiotics, oral' and 'antibiotics, topical' were merged into one item ('antibiotics, oral or topical'), and 'days lost from usual activities' and 'safety bloods' (as already included at baseline) were added as obvious follow‐up items making a total of 69 items mapped to 19 domains.

Discussion {#bjd16714-sec-0023}
==========

This Delphi exercise identified a core set of 19 domains containing 69 items recommended to be captured in existing and future AE patient registries with a research focus, which collect data from children and adults on photo‐ and systemic immunomodulatory therapies. Domains and items are related to demographics, AE diagnosis and treatment (past and current), family history, (allergic) comorbidities, concomitant medication, physical examination, physician‐ and patient‐reported outcomes, investigations, management and adverse events.

Strengths and limitations {#bjd16714-sec-0024}
-------------------------

Firstly, we registered and published our protocol and followed the COMET and COS‐STAR guidelines.[17](#bjd16714-bib-0017){ref-type="ref"} Secondly, we successfully involved a large number of participants from different stakeholder groups and countries, which strengthens the recommendations. Despite the strenuous challenge of keeping all participants on board, we maintained a good response rate. Further, by employing both an eDelphi exercise and a face‐to‐face consensus meeting, positive effects of anonymity (avoiding dominance of certain participants) and interaction were combined. Finally, patients were actively involved throughout the planning and conduct of the project.

Nevertheless, some limitations remain. Although we tried to avoid the risk of disproportionate representation among stakeholder groups, a higher number of clinicians participated compared with other groups. However, this overrepresentation was not a problem in the eDelphi because results were presented by stakeholder group. At the consensus meeting this point was consciously addressed by our facilitator who ensured all voices, especially of patients, were heard. Further, the number of researchers and regulatory body representatives was low. The dropout rates of both regulatory body and industry representatives were high; a possible explanation may be lower relevance of the eDelphi to these groups and lack of familiarity with the clinical area. Another potential limitation is that although dermatology societies from across the world were invited to participate, there was an overrepresentation of Western nationalities. This may limit the generalizability of the consensus and we cannot exclude the possibility that cross‐cultural differences were missed. Further, the survey was conducted only in English. To address this limitation, we involved patients and patient organizations in the development and pilot phase, used plain English where possible, included help texts in the survey, and provided a list with explanations of domains and items. Another consideration is the feasibility of this core set, given the number of domains and items included. In this context, it is important to highlight that this core set is not for clinical practice but for registries focused on research. Further, 49 domain items are measured only at baseline, leaving only 20 for follow‐up visits. Also, most of the domains and items are required by guidelines and many are already included as part of clinical visits. Above all, there is experience with the TREATgermany registry, which has been ongoing for a few years and has a bigger dataset than our core domains and items.

This internationally agreed core set has the potential to unify data collection across AE patient registries to allow for direct comparisons between countries as well as data sharing and pooling. Healthcare professionals and patients will benefit especially by the data generated on comparative effectiveness, safety and cost‐effectiveness of photo‐ and systemic immunomodulatory therapies across dermatology centres and country boundaries.

This core set is recommended to be used in all existing (currently only one, TREATgermany) and future AE patient registries with a research focus, and we encourage all stakeholders to endorse this recommendation as it will have impact only if it is consistently implemented.

Our research group is in the process of determining how the identified domains and items should be measured, defined and categorized. These results will be published separately. The final core set will be pilot tested for feasibility in 2018 to ensure we do not overburden colleagues. This may result in a more limited version of the current core set downstream. For updates of our work and for anyone who is interested in collaborating with us, please contact the TREAT Registry Taskforce via our website, treat‐registry‐taskforce.org.
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**Table S1.** Proposed domains and domain items for round 1 of the eDelphi questionnaire.

**Table S2.** Obvious domains and domain items.**Table S3.** Domain items after eDelphi rounds 2 and 3 as well as the consensus meeting.**Table S4.** Domain items that have reached consensus (*n* = 38, excluding *n* = 30 from obvious list) to be included in the core dataset with percentage scoring 7--9 and 1--3 at consensus meeting.**Fig S1.** (a) Example of how each item was presented in round 1 of the eDelphi. (b) Example of how results were fed back to participants in round 3 of the eDelphi.

###### 

Click here for additional data file.
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